Langton E - Search Results

1

Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.

Parker R, Schiemann AH, Langton E, Bulger T, Pollock N, Bjorksten A, Gillies R, Hutchinson D, Roxburgh R, Stowell KM. Parker R, et al. Among authors: langton e. J Neuromuscul Dis. 2017;4(2):147-158. doi: 10.3233/JND-170210. J Neuromuscul Dis. 2017. PMID: 28527222 Free PMC article.

2

Identification and Functional Analysis of RYR1 Variants in a Family with a Suspected Myopathy and Associated Malignant Hyperthermia.

Schiemann AH, Roesl C, Pollock N, Langton E, Bulger T, Stowell KM. Schiemann AH, et al. Among authors: langton e. J Neuromuscul Dis. 2020;7(1):51-60. doi: 10.3233/JND-190430. J Neuromuscul Dis. 2020. PMID: 31903994

3

Malignant hyperthermia and day stay surgery.

Pollock N, Langton E, McDonnell N, Tiemessen J, Stowell K. Pollock N, et al. Among authors: langton e. Anaesth Intensive Care. 2006 Feb;34(1):40-5. doi: 10.1177/0310057X0603400114. Anaesth Intensive Care. 2006. PMID: 16494148

4

Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update.

Barnes C, Stowell KM, Bulger T, Langton E, Pollock N. Barnes C, et al. Among authors: langton e. Anaesth Intensive Care. 2015 Jan;43(1):98-104. doi: 10.1177/0310057X1504300115. Anaesth Intensive Care. 2015. PMID: 25579296

5

Management of malignant hyperthermia susceptible parturients.

Pollock NA, Langton EE. Pollock NA, et al. Among authors: langton ee. Anaesth Intensive Care. 1997 Aug;25(4):398-407. doi: 10.1177/0310057X9702500413. Anaesth Intensive Care. 1997. PMID: 9288384

6

Suspected malignant hyperthermia reactions in New Zealand.

Pollock AN, Langton EE, Couchman K, Stowell KM, Waddington M. Pollock AN, et al. Among authors: langton ee. Anaesth Intensive Care. 2002 Aug;30(4):453-61. doi: 10.1177/0310057X0203000410. Anaesth Intensive Care. 2002. PMID: 12180584

7

Safety of exposure of malignant hyperthermia non-susceptible patients and their relatives to anaesthetic triggering agents.

Pollock N, Langton EE, Stowell KM, Bulger TF. Pollock N, et al. Among authors: langton ee. Anaesth Intensive Care. 2011 Sep;39(5):887-94. doi: 10.1177/0310057X1103900514. Anaesth Intensive Care. 2011. PMID: 21970134

8

Administration of anaesthetic triggering agents to patients tested malignant hyperthermia normal and their relatives in New Zealand: an update.

Frei D, Stowell KM, Langton EE, McRedmond L, Pollock NA, Bulger TF. Frei D, et al. Among authors: langton ee. Anaesth Intensive Care. 2017 Sep;45(5):611-618. doi: 10.1177/0310057X1704500512. Anaesth Intensive Care. 2017. PMID: 28911291

9

Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibility identified: missed opportunities prior to diagnosis.

Chan TY, Bulger TF, Stowell KM, Gillies RL, Langton EE, Street NE, Pollock NA. Chan TY, et al. Among authors: langton ee. Anaesth Intensive Care. 2017 Nov;45(6):707-713. doi: 10.1177/0310057X1704500610. Anaesth Intensive Care. 2017. PMID: 29137581

10

Perinatal diagnosis of malignant hyperthermia susceptibility.

Stowell K, Pollock N, Langton E. Stowell K, et al. Among authors: langton e. Anaesth Intensive Care. 2007 Jun;35(3):454-5. Anaesth Intensive Care. 2007. PMID: 17591153 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters